Evidence map›Paper›PMID 25855340›Full record

Trial reportDiabetes, obesity & metabolism2015

Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.

T R Pieber, S Deller, S Korsatko, L Jensen, E Christiansen, J Madsen, S R Heller

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01536665. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01536665 phase1completed

The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes

Ran2012Enrolled45Registered outcomes4Posted comparisons0ConditionsDiabetes, Diabetes Mellitus, Type 1Armsliraglutide, Placebo
PMID 27282158other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

T R PieberDivision of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria.
S DellerDivision of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria.
S KorsatkoDivision of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria.
L JensenNovo Nordisk A/S, Søborg, Denmark.
E ChristiansenNovo Nordisk A/S, Søborg, Denmark.
J MadsenNovo Nordisk A/S, Søborg, Denmark.
S R HellerAcademic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, UK.
Medical University of Graz · ATNovo Nordisk (Denmark) · DKUniversity of Sheffield · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo investigate the effect of glucagon-like peptide 1 receptor agonist liraglutide on the counter-regulatory hormone response to hypoglycaemia in type 1 diabetes.

methodsWe conducted a randomized, double-blind, placebo-controlled, single-centre trial, in which a total of 45 adults with type 1 diabetes [mean ± standard deviation age 34.5 ± 11.2 years, BMI 23.9 ± 2.4 kg/m(2) , glycated haemoglobin (HbA1c) 7.6 ± 0.8%, diabetes duration 16.6 ± 9.4 years] underwent a hypoglycaemic clamp after 4 weeks' crossover treatment with once-daily liraglutide/placebo added to insulin in one of three liraglutide dose groups: 0.6 mg (n = 15); 1.2 mg (n = 14); and 1.8 mg (n = 16). The main outcome measure was glucagon concentration at nadir plasma glucose (2.5 mmol/l). Clinical outcomes were also evaluated. Five participants were withdrawn from the trial; three because of adverse events. All participants were included in the analysis.

resultsGlucagon concentration at nadir plasma glucose was modest, trending towards lower concentrations at increasing liraglutide dose versus placebo: 34.7 versus 38.1 pg/ml, p = 0.555 (0.6 mg); 28.8 versus 37.2 pg/ml, p = 0.126 (1.2 mg); and 28.4 versus 37.5 pg/ml, p = 0.092 (1.8 mg). There was no difference, however, between liraglutide and placebo in incremental change in glucagon during hypoglycaemia. Other counter-regulatory hormone levels increased during hypoglycaemia with no systematic differences between groups. Glucose infusion rates were significantly lower with liraglutide versus placebo during the clamp. After 4 weeks' treatment, HbA1c remained unchanged in the liraglutide and placebo groups. Greater reductions in insulin dose and body weight were seen with liraglutide versus placebo.

conclusionsLiraglutide did not compromise hypoglycaemic responses in type 1 diabetes after 4 weeks' treatment.

Indexed as

AdultBody WeightCross-Over StudiesDiabetes Mellitus, Type 1Double-Blind MethodDrug Therapy, CombinationFemaleGlucagonGlucagon-Like Peptide 1GlucoseGlucose Clamp TechniqueGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsInsulinGlucagonGlucagon-Like Peptide 1GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulinLiraglutidecatecholaminescounter-regulationGLP-1glucagonglucose infusion ratehypoglycaemiahypoglycaemic clampincretin therapyliraglutidetype 1 diabetes

Identifiers

PMID25855340
OpenAlexW2124265017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.